The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Genentech
 
Honoraria - AstraZeneca, Boryung Pharmaceutical, Daiichi Sankyo, Roche, MSD
Consulting or Advisory Role - AstraZeneca, Boryung Pharmaceutical, Daiichi Sankyo, Pfizer, Lilly, Roche
Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial.
 
Rafal Dziadziuszko
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech; Takeda
Consulting or Advisory Role - GlaxoSmithKline
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Fabrice Barlesi
Consulting or Advisory Role - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai Europe (Inst); Lilly (Inst); Merck Serono (Inst); Mirati Therapeutics (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Jeong Eun Kim
Consulting or Advisory Role - Roche/Genentech
 
Shirish M. Gadgeel
Honoraria - Merck
Consulting or Advisory Role - Arcus Biosciences; AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Daichii-Sanyko; Eisai; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Novartis; Pfizer; Regeneron; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Blueprint Medicines (Inst); Calithera Biosciences (Inst); Daichii Sanyko (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Dragonfly Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Elevation Oncology (Inst); Erasca, Inc (Inst); Genentech/Roche (Inst); Helsinn Therapeutics (Inst); I-Mab (Inst); Incyte (Inst); InventisBio (Inst); Janssen Oncology (Inst); Merck; Merck (Inst); Mirati Therapeutics (Inst); Nektar (Inst); Nektar (Inst); Numab (Inst); Pfizer (Inst); Regeneron (Inst); Regeneron (Inst); Turning Point Therapeutics (Inst); Verastem (Inst); Ymabs Therapeutics Inc (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics
Other Relationship - AstraZeneca
 
Maciej Krzakowski
Consulting or Advisory Role - AstraZeneca, Ipsen, Roche
Speakers' Bureau - AstraZeneca, BMS, MSD
Travel, Accommodations, Expenses - Takeda, AstraZeneca, Gilead, Roche, Amgen
 
Jae Ho Jeong
No Relationships to Disclose
 
Gennaro Daniele
Travel, Accommodations, Expenses - Bayer
 
David Chen
No Relationships to Disclose
 
Youyou Hu
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Timothy R. Wilson
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Brian P. Simmons
Employment - Genentech/Roche
Stock and Other Ownership Interests - Roche/Genentech
 
David Morgan Thomas
Employment - Australian Unity; Omico
Honoraria - Roche
Research Funding - Amgen; AstraZeneca; Bayer; Elevation Oncology; George Clincal (Inst); InterVenn Biosciences; Lilly (Inst); Microba (Inst); Pfizer; Roche; Seagen (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - Amgen